Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | SWOG S1702: isatuximab for AL amyloidosis

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the results of the ongoing Phase II SWOG S1702 study (NCT03499808) which examined the role of the anti-CD38 monoclonal antibody isatuximab in patients with relapsed/refractory amyloid light-chain (AL) amyloidosis. Isatuximab was well tolerated with some grade one or two infusion-related adverse events. The overall hematologic response rate was 77%, where one patient achieved hematological complete response (CR) in a median of 1.1 months. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.